Skip to main content
SpringerLink
Log in

Der selektive Verzicht auf die neoadjuvante Radio(chemo)therapie beim Rektumkarzinom entbehrt der Evidenz

The selective waiving of neoadjuvant (chemo)radiotherapy for rectal cancer lacks evidence

  • Leserbriefe
  • Published:
Der Chirurg Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Benson AB 3rd, Venook AP, Bekaii-Saab T et al (2015) Rectal Cancer, Version 2.2015. J Natl Compr Canc Netw 13:719–728 (quiz 28)

    PubMed  Google Scholar 

  2. Bundschuh RA, Dinges J, Neumann L et al (2014) Textural parameters of tumor heterogeneity in (1)(8)F-FDG PET/CT for therapy response assessment and prognosis in patients with locally advanced rectal cancer. J Nucl Med 55:891–897

    Article  CAS  PubMed  Google Scholar 

  3. Combs SE, Nusslin F, Wilkens JJ (2016) Individualized radiotherapy by combining high-end irradiation and magnetic resonance imaging. Strahlenther Onkol 192:209–215

    Article  PubMed  Google Scholar 

  4. Droge LH, Weber HE, Guhlich M et al (2015) Reduced toxicity in the treatment of locally advanced rectal cancer: a comparison of volumetric modulated arc therapy and 3D conformal radiotherapy. BMC Cancer 15:750

    Article  PubMed  PubMed Central  Google Scholar 

  5. Eriksen MT, Wibe A, Haffner J et al (2007) Prognostic groups in 1,676 patients with T3 rectal cancer treated without preoperative radiotherapy. Dis Colon Rectum 50:156–167

    Article  PubMed  Google Scholar 

  6. Kulu Y, Hackert T, Debus J et al (2016) Role of neoadjuvant radiotherapy for rectal cancer : Is MRI-based selection a future model? Chirurg 87(7):573–578

    Article  CAS  PubMed  Google Scholar 

  7. Kulu Y, Tarantino I, Billeter AT et al (2016) Comparative outcomes of Neoadjuvant treatment prior to total mesorectal excision and total mesorectal excision alone in selected stage II/III low and mid rectal cancer. Ann Surg Oncol 23:106–113

    Article  PubMed  Google Scholar 

  8. Leccisotti L, Gambacorta MA, De Waure C et al (2015) The predictive value of 18 F-FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy. Eur J Nucl Med Mol Imaging 42:657–666

    Article  CAS  PubMed  Google Scholar 

  9. Ngan SY, Burmeister B, Fisher RJ et al (2012) Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 30:3827–3833

    Article  PubMed  Google Scholar 

  10. Pox C, Aretz S, Bischoff SC et al (2013) S3-guideline colorectal cancer version 1.0. Z Gastroenterol 51:753–854

    Article  CAS  PubMed  Google Scholar 

  11. Rodel C, Graeven U, Fietkau R et al (2015) Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16:979–989

    Article  PubMed  Google Scholar 

  12. Samuelian JM, Callister MD, Ashman JB et al (2012) Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 82:1981–1987

    Article  PubMed  Google Scholar 

  13. Sauer R, Liersch T, Merkel S et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30:1926–1933

    Article  CAS  PubMed  Google Scholar 

  14. Sautter-Bihl ML, Hohenberger W, Fietkau R et al (2014) MRI-based treatment of rectal cancer: is prognostication of the recurrence risk solid enough to render radiation redundant? Ann Surg Oncol 21:197–204

    Article  PubMed  Google Scholar 

  15. Sebag-Montefiore D, Stephens RJ, Steele R et al (2009) Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373:811–820

    Article  PubMed  PubMed Central  Google Scholar 

  16. Taylor FG, Quirke P, Heald RJ et al (2014) Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5‑year follow-up results of the MERCURY study. J Clin Oncol 32:34–43

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für RadioOnkologie und Strahlentherapie, Technische Universität München (TUM), Ismaninger Straße 22, 81675, München, Deutschland

    D. Habermehl

Authors
  1. D. Habermehl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Habermehl.

Ethics declarations

Interessenkonflikt

D. Habermehl gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Habermehl, D. Der selektive Verzicht auf die neoadjuvante Radio(chemo)therapie beim Rektumkarzinom entbehrt der Evidenz. Chirurg 87, 884–886 (2016). https://doi.org/10.1007/s00104-016-0279-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00104-016-0279-x

Search

Navigation